Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study
2024

Respiratory Outcomes of Gene Therapy for Spinal Muscular Atrophy

Sample size: 25 publication 10 minutes Evidence: moderate

Author Information

Author(s): Moran Lavie, Mika Rochman, Keren Armoni Domany, Inbal Golan Tripto, Be’er Moria, Omri Besor, Liora Sagi, Sharon Aharoni, Mira Ginsberg, Iris Noyman, Hagit Levine

Primary Institution: Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Hypothesis

Does onasemnogene abeparvovec treatment improve respiratory outcomes in pediatric patients with spinal muscular atrophy?

Conclusion

The study suggests that onasemnogene abeparvovec may improve respiratory outcomes in pediatric patients with spinal muscular atrophy.

Supporting Evidence

  • Respiratory-related hospitalizations decreased by 26% after treatment.
  • Average daily ventilation time decreased from 14.3 to 11.1 hours.
  • Ten out of 23 patients required non-invasive ventilation after one year.

Takeaway

This study looked at kids with a disease that makes it hard to breathe and found that a new treatment might help them breathe better.

Methodology

This was a multicenter retrospective cohort study assessing respiratory outcomes in SMA patients treated with onasemnogene abeparvovec over one year.

Potential Biases

Variability in treatment protocols across different centers may introduce bias.

Limitations

The small sample size limits the ability to draw definitive conclusions, and the study's observational nature may introduce variability in care.

Participant Demographics

The cohort included 25 pediatric patients, primarily with SMA type 1, with a median age of 6.1 months at treatment initiation.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s00431-024-05886-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication